In COVID-19 clinical update #47, Daniel Griffin reviews phase 3 results for Novavax and J&J vaccines, transmission in K-12 settings in Wisconsin, data on Lilly and Regeneron monoclonal antibody therapy, and a study of colchicine for treatment of disease.
Gisa, Steffi, and César join TWiV to discuss their careers, their research, and the COVID-19 pandemic in Germany.
The TWiVers review Biden’s national strategy for COVID-19 responses and pandemic preparedness, and an evaluation of the BinaxNOW rapid antigen test for SARS-CoV-2 infection.
In COVID-19 clinical update #46, Daniel Griffin discusses the BinaxNow rapid antigen test, efficacy of Bamlanivimab in nursing homes, associations of serum vitamin D concentrations with in-hospital mortality and need for invasive mechanical ventilation, trials of IL-6 receptor antagonists, effects of anticoagulants on in-hospital mortality, and symptom persistence in outpatients.
In this episode, President Biden elevates his science advisor to his Cabinet, a review of the current flu season, the scientific goals of the WHO-convened Global Study of the Origins of SARS-CoV-2, and answers to listener questions.
In COVID-19 clinical update #45, Daniel Griffin discusses J&J Ad26 vaccine results, reactogenicity after the second dose of mRNA vaccines, expansion of vaccine eligibility, and the finding that encephalitis after SARS-CoV-2 infection is a cytokine release syndrome.
TWiV answers listener questions about pandemic response, excess deaths in 25-44 year olds, vaccines, vaccines, and vaccines.
In this COVID-19 clinical update, Daniel Griffin summarizes current status of vaccination in the US, discusses a study on convalescent sera from Argentina, use of remdesivir in patients with kidney disease, and provides further considerations on the use of Ct values in patient management.
On this episode, a discussion of why modifying the dose schedule of the mRNA vaccines in the US is not a good idea, evidence that lower Ct values on hospital admission is associated with higher mortality, and dose-dependent response to SARS-CoV-2 infection of ferrets.
In Daniel Griffin’s final clinical report for 2020, he summarizes what we have learned about the clinical management of COVID-19 patients in the past year.